**丁二胍**，又名丁双胍，药品名**丁福明**，是一种口服降血糖药，於1957年被合成\[1\]，主要用于二型[糖尿病的治疗](../Page/糖尿病.md "wikilink")，与[二甲双胍](../Page/二甲双胍.md "wikilink")、[苯乙双胍同属于双胍类口服降血糖药](https://zh.wikipedia.org/wiki/苯乙双胍 "wikilink")。

## 化学性质

盐酸丁二胍是白色或黄色，无味，[晶体粉末](../Page/晶体.md "wikilink")，嚐起來有微酸苦味。

[熔点](https://zh.wikipedia.org/wiki/熔点 "wikilink") 174 到
177°C，为[强碱](https://zh.wikipedia.org/wiki/强碱 "wikilink")，可溶于[水](../Page/水.md "wikilink")、[甲醇](../Page/甲醇.md "wikilink")、[乙醇](../Page/乙醇.md "wikilink")，不溶于[氯仿和](../Page/氯仿.md "wikilink")[醚类](https://zh.wikipedia.org/wiki/醚类 "wikilink")\[2\]\[3\]。

[分配系数](../Page/分配系数.md "wikilink") (log P 辛醇-水) -1.20E+00；水溶性在25°C为
7.46E+05 毫克/升。[蒸汽压于](https://zh.wikipedia.org/wiki/蒸汽压 "wikilink")25°C 为
1.64E-04 毫米汞柱 (估计值)。

## 作用机理

盐酸丁二胍能够延迟肠胃途径的糖吸收，增加胰岛素敏感性和细胞的糖摄入，并且抑制肝糖合成。盐酸丁二胍和其他双胍类口服降糖药一样，不是以直接降血糖为主要作用机理，而是对抗血糖水平过高。服用不会产生低血糖的现象，但能够有效降低糖尿病人的空腹与餐后血糖\[4\]。

## 剂量

日常给药剂量为 150–300 毫克 口服\[5\]。

## 副作用与用药禁忌

常见副作用为食欲匮乏，恶心，腹泻，口中有金属味和体重减轻。有糖尿病昏迷，[酮酸中毒](../Page/酮酸中毒.md "wikilink")，严重感染或创伤者禁用。

## 毒性

盐酸丁二胍由于可能导致乳酸堆积的機率增加，而在一些国家被下市。目前在[罗马尼亚](https://zh.wikipedia.org/wiki/罗马尼亚 "wikilink")、[匈牙利](../Page/匈牙利.md "wikilink")、[台湾和](https://zh.wikipedia.org/wiki/台湾 "wikilink")[日本仍作为](../Page/日本.md "wikilink")[处方药被应用](https://zh.wikipedia.org/wiki/处方药 "wikilink")。\[6\]\[7\]\[8\]\[9\]\[10\]\[11\]乳酸堆积症一般只在盐酸丁二胍血浆浓度超过的
0.60 微克/毫升的病人中发生，在肾功能正常的患者中十分罕见。\[12\]\[13\]\[14\]

## 抗癌作用

盐酸丁二胍和[二甲双胍还有](../Page/二甲双胍.md "wikilink")[苯乙双胍一样](https://zh.wikipedia.org/wiki/苯乙双胍 "wikilink")，抑制癌细胞生长和发育\[15\]\[16\]\[17\]\[18\]\[19\]。其抗癌机制是由于其可以阻断[瓦氏效应](https://zh.wikipedia.org/wiki/瓦氏效应 "wikilink")，并且将癌细胞的供能途径从细胞基质糖解逆转回依靠线粒体的丙酮酸途径。\[20\]
\[21\]

## 参考文献

[Category:胍](https://zh.wikipedia.org/wiki/Category:胍 "wikilink")
[Category:糖尿病藥物](https://zh.wikipedia.org/wiki/Category:糖尿病藥物 "wikilink")

1.  Seymour L. Shapiro et al. Salts Of N-Amylbiguanide. US Patent
    number: 2961377; Filing date: Aug 5, 1957; Issue date: 1960
2.  Jacker HJ. \[New Pharmacologic Products. 2. Buformin For Oral
    Therapy Of Diabetes\]. Pharm Prax. 1964;10:247-9.
3.  Eustace George Coverly Clarke, Judith Berle, Pharmaceutical Society
    of Great Britain. Dept. of Pharmaceutical Sciences. Isolation and
    identification of drugs in pharmaceuticals, body fluids and
    post-mortem material, Volume 1. Pharmaceutical Press 1974, p226
4.  Enrique Ravina, Hugo Kubinyi. The Evolution of Drug Discovery: From
    Traditional Medicines to Modern Drugs. Wiley. 2011 p 215
5.  Gustav Kuschinsky, Heinz Lüllmann. Textbook of pharmacology.
    Academic Press p 225, 1973
6.  Hankó B, Tukarcs E, Kumli P, Vincze Z. Antidiabetic drug utilization
    in Hungary. Pharm World Sci. 2005 Jun;27(3):263-5.
7.  Hankó BZ, Reszegi CA, Kumli P, Vincze Z. \[Practice of antidiabetic
    therapy in Hungary\]. Acta Pharm Hung. 2005;75(2):77-86.
8.  Jerry L. Schlesser, Gale Research Inc. Drugs available abroad.
    Derwent Publications, Ltd - 1990 p28
9.
10. Chou CH, Cheng CL, Huang CC. A validated HPLC method with
    ultraviolet detection for the determination of buformin in plasma.
    Biomed Chromatogr. 2004 May;18(4):254-8.
11. [Takeda Announces Submission Of Application For Additional
    Indication Of Actos In Japan; Concomitant Therapy With Biguanides
    For Type 2 Diabetes. Medical News Today. 28
    Jan 2007](http://www.medicalnewstoday.com/articles/61752.php)
12. Wittmann P, Haslbeck M, Bachmann W, Mehnert H. \[Lactic acidosis in
    diabetics on biguanides (author's translation)\] Deutsche
    Medizinische Wochenschrift 102(1):5-10, 1977
13. Berger W, Mehnert-Aner S, Mülly K, Heierli C, Ritz R. \[10 cases of
    lactic acidosis during biguanide therapy (buformin and
    phenformin)\]. Schweizerische medizinische Wochenschrift.
    106:1830-1834, 1976
14.
15. Sakae Saito, Aki Furuno, Junko Sakurai, Asami Sakamoto, Hae-Ryong
    Park, Kazuo Shin-ya, Takashi Tsuruo, and Akihiro Tomida. Chemical
    Genomics Identifies the Unfolded Protein Response as a Target for
    Selective Cancer Cell Killing during Glucose Deprivation. Cancer
    Research 2009;69(10):4225–34
16. Vladimir N. Anisimov. Insulin/IGF-1 signaling pathway driving aging
    and cancer as a target for pharmacological intervention.
    Experimental Gerontology Volume 38, Issue 10, October 2003, Pages
    1041-1049
17. Valery A. Alexandrov, Vladimir N. Anisimov, Natalia M. Belous, Inna
    A. Vasilyeva and Vera B. Mazon. The inhibition of the transplacental
    blastomogenic effect of nitrosomethylurea by postnatal
    administration of buformin to rats. Carcinogenesis Volume 1, Issue
    12 Pp. 975-978, 1980
18. Anisimov VN, Ostroumova MN, Dil'man VM. Inhibition of the
    blastomogenic effect of 7,12-dimethylbenz(a)anthracene in female
    rats by buformin, diphenin, a polypeptide pineal extract and L-DOPA.
    Bulletin of Experimental Biology and Medicine. Volume 89, Number 6,
    819-822, 1980
19. Vladimir N. Anisimov, Lev M. Berstein, Irina G. Popovich, Mark A.
    Zabezhinski, Peter A. Egormin, Margarita L. Tyndyk, Ivan V. Anikin,
    Anna V. Semenchenko, Anatoli I. Yashin. Central and Peripheral
    Effects of Insulin/IGF-1 Signaling in Aging and Cancer: Antidiabetic
    Drugs as Geroprotectors and Anticarcinogens. Annals of the New York
    Academy of Sciences. 1057:220-234, 2005
20. Matthew G. Vander Heiden, Lewis C. Cantley, and Craig B. Thompson.
    Understanding the Warburg Effect: The Metabolic Requirements of Cell
    Proliferation. Science 324 (5930): 1029-1033, 2009.
21. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA,
    Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis
    in liver and therapeutic effects of metformin. Science. 2005 Dec
    9;310(5754):1642-6.